PRODUCT INFORMATION

UNBS5162

Item No. 17739

CAS Registry No.:	956590-23-1
Formal Name:	N-[2-[2-(dimethylamino)ethyl]-2,3-dihydro-1,3-dioxo-1H-benz[de]isoquinolin-5-yl]-urea
MF:	$C_{17}H_{18}N_4O_3$
FW:	326.4
Purity:	≥98%
UV/Vis.:	λ_{max}: 226, 249, 339, 384 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

UNBS5162 is supplied as a crystalline solid. A stock solution may be made by dissolving the UNBS5162 in the solvent of choice, which should be purged with an inert gas. UNBS5162 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of UNBS5162 in these solvents is approximately 2 and 3 mg/ml, respectively.

UNBS5162 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, UNBS5162 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. UNBS5162 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

UNBS5162 is a naphthalimide that antagonizes the expression of CXCL chemokines. *In vitro* exposure of PC-3 prostate cancer cells to 1 µM UNBS5162 for five successive days was shown to decrease the expression of proangiogenic CXCL chemokines.[1] UNBS5162 also demonstrates antiangiogenic properties *in vivo* in an orthotopic PC-3 model.[1]

Reference

1. Mijatovic, T., Mahieu, T., Bruyère, C., *et al.* UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. *Neoplasia* **10(6)**, 573-586 (2008).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM